Our Therapeutics Pipeline

Current research works

Our current research works

Since the beginning of 2022 CancerAppy has focused on the discovery and development of new therapeutic targets in cancer.

All this thanks to the development of our AI platform in collaboration with our scientific advisors.


Identified a Therapeutic Target in Breast Cancer Triple Negative with clear oncogenic role.


Identified CA02- CA03, two membrane proteins that are upregulated in NSCLC with K-RAS G12C mutation and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies.


Developing CA04 an Antibody and Antibody Drug Conjugates against Therapeutic Target in Pancreatic Cancer, with clear oncogenic role.


We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.

Current Research Projects



Preclinical development

Clinical Phase

Target Identification

Target Validation

Early research

Lead up

Late research

IND enable

  • CA01 – TNBC
  • CA02-03 Lung cancer
  • CA04 Pancreatic cancer
  • CA05 Lung Cancer

Target Identification

We combine our expertise in biology and AI to help you to identify new therapeutic targets.

Lead Identification

We combine our expertise in chemistry and AI to help you to identify new therapeutic targets.

Mechanism of action

We help you to find the possible mechanism of action of your compound. 

If you are interested in identifying therapeutic targets or developing new drugs, do not hesitate to contact us.

We can help you.

We want to help you.

Request an Interview

We would be happy to help you.